Introduction
Hepatocyte growth factor (HGF) was initially discovered as a potent mitogen of rat hepatocytes in primary culture [24, 25] . HGF induces mitogenesis, motogenesis, and morphogenesis in various cell types via interaction with its functional receptor, c-Met [2, 12] . Several in vitro studies have indicated that HGF also stimulates the scattering and migration of cancer cells [20, 23] . Abnormal signaling via HGF/c-Met is responsible for many types of cancers, and elevated levels of circulating HGF have been correlated with tumor metastasis and cancer progression [32, 34] . Considerable effort has been expended searching for specific inhibitors of the HGF/c-Met pathway, in development of novel therapeutic agents for treating various cancers [6, 13] . Inhibitors of c-Met tyrosine kinase have shown promising efficacy in preclinical and clinical trials. In addition to small-molecule inhibitors, antibodies directed against HGF and c-Met are also under development [7, 17, 22, 28 ].
An early study claimed that a minimum of three antibodies directed against different epitopes are required to completely inhibit c-Met activation [5] . Indeed, the development of novel, high-potency therapeutic antibodies has been a long-standing challenge in the pharmaceutical industry, because each antibody recognizes a specific epitope and thus produces a distinct clinical outcome. Nevertheless, several monoclonal antibodies (mAbs) blocking the HGF/ c-Met signaling pathway have been developed, and their tumor-suppression activities have been demonstrated in xenograft mouse models [3, 16, 19] , confirming the feasibility of using HGF-neutralizing antibodies to block c-Met activation. Among the HGF-neutralizing antibodies, the recombinant mAb SFN68, generated by immunizing rabbits with the HGF/c-Met complex, is quite unique in that it is more specific to the HGF/c-Met interaction than other antibodies elicited by immunizing with HGF only [15] . The cDNA for SFN68 was constructed to produce an intact antibody composed of rabbit/human chimeric Fab and human IgG 1 Fc fragments. The resulting chimeric SFN68 mAb, recognizing a nonlinear epitope, effectively interfered with HGF/c-Met interaction in a cell-based assay [15] . The SFN68 antibody was further engineered to generate a humanized anti-HGF antibody, named YYB-101 (also known as ABX101), which we sought to produce in large-scale bioreactors for use in toxicity and efficacy studies.
Here, we describe an optimized bioprocess for the production of humanized anti-HGF YYB-101 mAb using recombinant Chinese hamster ovary (CHO) cells. We optimized the bioprocessing medium using diverse chemically defined basal and feed media and established an optimal feeding strategy. In addition, the bioreactor operation conditions were optimized in a 5 L bioreactor, and the established optimal conditions were further verified in a 200 L bioreactor. Finally, the antitumor activity of purified YYB-101 was confirmed using a cell-based HGF-neutralization assay and a xenograft mouse model involving implantation with human glioblastoma cells.
Materials and Methods

Cell Lines and Culture Media
The CHO cell line CHO-YYB-101, which expresses the humanized anti-HGF YYB-101 mAb, was generated by iBio Co., Ltd., Seoul, Korea. Briefly, the CHO-YYB-101 cell line was established by transfecting the serum-free suspension cultureadapted dihydrofolate reductase (DHFR)-deficient CHO cell line DG44 (Invitrogen, Carlsbad, CA, USA) with an expression vector harboring the cDNA encoding YYB-101 under control of the cytomegalovirus (CMV) promoter, the DHFR-coding gene required for gene amplification using methotrexate (MTX), and a neomycin resistance gene as a selection marker (J.H. Chung et al., unpublished data; full details will be reported elsewhere). The transfected cells were selected in the presence of 250 mg/ml of G418 for 3-4 weeks, and the transfected gene was amplified by selecting clones adapted to grow in medium containing 1-2 mM MTX (SigmaAldrich, St. Louis, MO, USA). Isogenic high-producers were then isolated from among the MTX-resistant clones using the limitingdilution method. For optimization of the medium, eight different chemically defined basal media were used, including CD OptiCHO (Invitrogen), CDM4CHO (Hyclone, Logan, UT, USA), CDM4mab (Hyclone), PowerCHO (Lonza, Verviers, Belgium), ProCHO5 (Lonza), ExCell 302 (SAFC Biosciences, Lenexa, KS, USA), ExCell DHFR (SAFC Biosciences), and ExCell CD (SAFC Biosciences). The feed media used included CHO CD Efficient Feed A, B, and C (Invitrogen), Cell Boost kit (Hyclone), and Xtreme (Lonza). Each feed medium was added to the individual basal medium to a final concentration of 10% (v/v) on day 0. When two different feed media were supplemented together, they were combined to a final concentration of 5% each. All media used for CHO cell cultivation were supplemented with 8 mM L-glutamine. The human malignant glioblastoma cell line U87 MG was obtained from the American Type Culture Collection (ATCC) (Manassas, VA, USA) and cultured as previously described [27] . Mink lung epithelial cells (Mv-1-Lu; ATCC CCL-64) were cultured in Dulbecco's Modified Eagle's Medium supplemented with 10% heat-inactivated fetal bovine serum and 4 mM L-glutamine at 37 o C in a 5% CO 2 atmosphere.
Cell Culture for Antibody Production
Screening for optimal basal and feed media and establishment of an optimal feeding strategy were carried out using parallel cultures in 125 ml shake flasks with a 30 ml working volume. Shake flasks were cultured at 37 o C with agitation at 130 rpm in a humidified atmosphere of 8% CO 2 using a Multitron incubator (Infors AG, Bottmingen, Switzerland). Fed-batch culturing was carried out in a 5-L BIOSTAT B Plus bioreactor (Sartorius, AG, Göttingen, Germany) with a 3-L working volume. Gas was provided through a ring sparger, and agitation was provided by a marine impeller with a diameter of 65 mm. For each bioreactor run, an inoculum culture was passed two times in CD OptiCHO medium and then seeded in the bioreactor at a density of 0.3-0.4 × 10 6 cells/ml. The bioreactor was operated at 37 o C, with agitation at 75 rpm and aeration at 50 ml/min through the sparger. Aeration was adjusted to 200 ml/min when the cells reached the maximum oxygen-consuming stage. Dissolved oxygen (DO) was maintained at 40% or 70%, depending on the test conditions. The pH was maintained at each set point by controlling the level of incoming CO 2 and by addition of 7.5% sodium bicarbonate. Feed medium was added according to the schedules determined during the medium optimization studies. The feed medium was added to the bioreactor at a rate of 2 ml/min to avoid oxygen depletion. Analytical samples were taken from the bioreactors daily, centrifuged, and stored at 20 o C until analysis. 
Analytical Methods for Monitoring Cell Culture Profiles
Cell number and viability were determined using an Innovatis Cedex Cell Counter XS (Roche Applied Science, Mannheim, Germany). Glucose, glutamine, and lactate concentrations were measured by enzymatic reactions using a YSI 7100 Multiparameter Bioanalytical System (YSI Life Sciences, Yellow Springs, OH, USA). The specific metabolic rate was determined by plotting measured values against the integral of viable cells, as previously described [30] .
Antibody Purification and Protein Analysis
Collected culture broth was clarified using 10SP and 90ZA depth filters (3M Purification Inc., Meriden, CT, USA) to remove cells and debris. The clarified culture broth was loaded onto a Mabselect SuRe Protein A column (GE Healthcare, Uppsala, Sweden) equilibrated with 20 mM sodium phosphate (pH 7.0). After washing with 20 mM sodium phosphate (pH 7.0) containing 1 M NaCl, bound antibodies were eluted with 20 mM citrate (pH 3.5). The pH of the eluted fractions was adjusted to 6.5 with 1 M Tris-HCl buffer (pH 9.0). The eluted fraction was applied to an SP Sepharose HP cation-exchange column (GE Healthcare) equilibrated with 20 mM sodium phosphate (pH 6.5) containing 20 mM NaCl. After washing with 20 mM sodium phosphate (pH 6.5) containing 60 mM NaCl, proteins were eluted with the same buffer containing 150 mM NaCl. The pH of the eluted fraction was adjusted to 7.2 and then applied to a Q Sepharose HP anion exchange column (GE Healthcare) equilibrated with 20 mM sodium phosphate (pH 7.2) containing 150 mM NaCl. The flowthrough fraction was collected. A Viresolve Pro membrane (Millipore, Billerica, MA, USA) was used to remove any viruses present in the flow-through fraction. Finally, the bulk antibody product was concentrated using a 30 kDa molecular mass cut-off Pellicon 3 ultrafiltration membrane (Millipore). The buffer was then exchanged by diafiltration using 12 vol of final formulation buffer (20 mM sodium phosphate, pH 7.2, 150 mM NaCl).
The quality of the purified antibodies was assessed using sizeexclusion chromatography (SEC) on a Zenix-C SEC-300 column (7.8 × 300 mm, 3 µm; Sepax Technology, Newark, DE, USA) connected to a Waters high-performance liquid chromatography (HPLC) system (Waters, Milford, MA, USA) equipped with a photodiode array (PDA) detector. Antibodies loaded onto the column were eluted using 100 mM sodium phosphate (pH 7.0) and 100 mM NaCl as the mobile phase. Protein elution was monitored at 280 nm. For cation-exchange HPLC, samples were separated using a ProPac WCX-10 weak cation-exchange column (Dionex, CA, USA) connected to a Waters HPLC system equipped with a PDA detector. Mobile phases A and B consisted of 20 mM HEPES buffer (pH 7.0) and 20 mM HEPES buffer with 1 M NaCl (pH 7.0), respectively. Proteins were eluted with a gradient from 85% to 0% mobile phase A over 35 min, followed by a wash with mobile phase B buffer (100%) at a flow rate of 0.5 ml/min.
Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis, Western Blot Analysis, and Enzyme-Linked Immunosorbent Assay SDS-PAGE was carried out using 4-12% NuPAGE Bis-Tris polyacrylamide gels (Invitrogen), and proteins were visualized by Coomassie Brilliant Blue staining. For western blot analysis, proteins were electrotransferred onto a polyvinylidene difluoride membrane (Invitrogen). The membrane was blocked for 2 h at room temperature with 5% skim milk in Tris-buffered saline containing 0.05% Tween 20 (TBST) and then washed three times with TBST (10 min each). The membrane was then incubated for 1 h in blocking buffer containing goat anti-human IgG (KPL, Gaithersburg, MD, USA). After washing with TBST, the membrane was incubated for 1 h in blocking buffer containing the secondary antibody, horseradish peroxidase (HRP)-conjugated rabbit antigoat IgG (H+L) (KPL), diluted 1:5,000 with blocking buffer. After washing with TBST, the membrane was incubated with TMB membrane substrate (KPL) to visualize the anti-HGF mAb.
The titer of anti-HGF mAb in the culture supernatant was determined by ELISA. Briefly, 96-well Maxisorp microtiter plates (Nunc, Roskilde, Denmark) were coated overnight at 4 o C with 100 µl of 1.0 mg/ml of goat anti-human IgG Fc (KPL) dissolved in 0.1 M carbonate buffer (pH 9.6). The plates were washed three times with phosphate-buffered saline (PBS) containing 0.05% Tween 20, blocked with PBS containing 1% bovine serum albumin (BSA) for 1 h, and incubated with 100 µl of appropriate culture supernatant for 1 h at 37 o C. The plates were then washed, and incubated with HRP-conjugated goat anti-human IgG antibody (KPL) for 1 h, after which TMB substrate solution (KPL) was added to allow for color development. After 10 min, the reaction was stopped by adding 2 N H 2 SO 4 . Absorbance was measured at 450 nm using a microplate reader. Data were analyzed using Gen5 software (BioTek, Winooski, VT, USA).
Cell-Based HGF-Neutralizing Activity Assay
The biological activity of the anti-HGF mAb was determined by measuring its ability to reverse the transforming growth factor (TGF)-β-induced growth inhibition mediated by HGF. The assay method was established by slight modification of the previously reported method [1, 29] . A total of 1 × 10 4 CCL-64 lung epithelial cells were seeded per well in a 96-well plate and treated with 1.25 ng/ml of human TGF-β1 (ProSpec-Tany TechnoGene Ltd., Ness-Ziona, Israel). In a separate plate, human HGF (ProSpecTany TechnoGene Ltd.) at a concentration of 250 ng/ml was preincubated for 1 h at 37 o C with 2-fold serial dilutions of purified antibody (0-10 µg/ml). The mixture containing free HGF not neutralized by the antibody was then added to the TGF-β1-treated CCL-64 cells and incubated for 72 h, after which cell proliferation was measured using a modified MTT assay with CCK-8 solution (Dojindo Laboratories, Kumamoto, Japan) according to the manufacturer's instructions. ) was determined using the formula (length × width 2 )/2, where length represents the longest axis and width represents the measurement at a right angle to the length. Data were expressed as the mean tumor volume ± SE for each treatment group.
Antitumor Activity Assay Using a Xenograft Mouse Model
Results
Optimization of Basal Medium by Formulation of Chemically Defined Media
To maximize anti-HGF YYB-101 mAb production, we sought to optimize the basal medium by combining CD OptiCHO basal medium, in which the YYB-101-producing 
Effects of Feed Media and Feeding Strategy on Antibody Production
Having selected the three different basal media formulations, we tested the effect of feed supplementation on antibody production by adding each of 10 different feed media to each of the optimized basal medium formulations to a final concentration of 10% (v/v). When antibody titers were assessed at day 12 in batch cultures, the highest antibody titer achieved in the feed medium screening experiments was 635 mg/l (Fig. 1) . This improvement, which represented a >4-fold increase over the titer achieved with the OptiCHO:CD FortiCHO (4:6) basal medium (155 mg/l), was observed by feeding with CHO CD Efficient Feed B. Feed B also enhanced the titer most effectively when added to CDM4MAb medium, yielding an antibody titer of 597 mg/l. Although the CD OptiCHO:PowerCHO2 (2:8) medium yielded the highest antibody titer in basal medium screening (Table 1) , antibody productivity was not enhanced as much as with the other two basal medium formulations when feed was added. We thus selected the CD OptiCHO:CD FortiCHO (4:6) formulation with 10% CHO CD Efficient Feed B as a production medium for use in subsequent fed-batch experiments.
Next, we sought to establish the optimal feeding schedules to improve antibody productivity. As summarized in Table 2 and Fig. 1 , addition of either CHO CD Efficient Feed B or C medium to the production medium described above had the greatest effect on enhancing the antibody titer. The maximum feed concentration was limited to 20% (v/v), because both Feed B and Feed C inhibited cell growth at concentrations over 25% in the production medium (data not shown). The antibody titers obtained after cultivation for 14 days under different feeding schedules are summarized in Table 2 . Overall, CHO CD Efficient Feed B yielded higher antibody titers than CHO CD Efficient Feed C under the same feeding schedule. By feeding CHO CD Efficient Feed B at 5% (v/v) each time on days 0, 2, 4, and 6, we obtained the highest antibody titer (757 mg/l). We thus used this feeding schedule in the subsequent bioprocess optimization experiments. 
Bioprocess Optimization for Large-Scale Production of Humanized Anti-HGF YYB-101 mAb
Using the optimized production medium and feeding schedule, we tested the effect of DO on the growth of YYB-101-producing CHO cells and antibody yield in a 5 L stirred bioreactor. During fed-batch operation of this reactor, glucose was supplemented, if necessary, to prevent the concentration from falling below 10 mM. The DO concentration was controlled at either 40% or 70% of air saturation, and the pH was maintained at 7.0. As shown in Figs. 2A and 2B, at both DO levels, the cell growth and viability profiles were similar, whereas the antibody titer increased by 17.6% at a DO of 70% of air saturation at day 13 (408 and 480 mg/l at 40% and 70% DO, respectively).
To determine the optimal pH, fed-batch cultures were operated at a DO of 70% of air saturation. The pH of the culture medium was controlled at 6.8, 7.0, or 7.2. Alternatively, the pH was shifted from 7.2 to 7.0 at day 2. As shown in Fig. 3 , under the pH shift condition, we obtained the highest antibody titer (737 mg/l), which was a 44% increase over the titers achieved at pH 7.0 or 7.2. This greater volumetric productivity was associated with an increase in viable cell number beginning at day 7. However, it should be noted that productivity was not improved at pH 7.0, even though the viable cell number was always higher than in the pH-shifted cultures. Our time-course data suggested that shifting the pH from 7.2 to 7.0 during the early stage of the culture is important for accelerating cell growth and maintaining cell viability longer in order to control overgrowth and improve antibody production.
For testing the in vivo efficacy of YYB-101, we produced the antibody in a 200 L single-use bioreactor operated at 37 o C, a DO of 70% of air saturation, and with pH shifting (pH shift from 7.2 to 7.0 on day 2). As in the case of the 5 L bioreactor, the same feed was added four times, on days 0, 2, 4, and 6. Under these conditions, which were optimized with a 5 L bioreactor, we obtained 830 mg/l of antibody after cultivation for 14 days, with an increased maximal viable cell number compared with that of the 5 L reactor (1.02 × 10 7 cells/ml vs. 1.25 × 10 7 cells/ml), although the specific growth rates were similar in both reactors (Table 3) . In addition, similar specific productivities obtained with both reactors (9.454 and 9.444 pg/cell/day in the 5 L and 200 L reactors, respectively). Of note, despite the similar growth rates in these reactors, the specific glucose consumption, lactate production, and ammonia production rates were higher in the 200 L reactor, likely due to the higher cell density and antibody titer in the 200 L bioreactor.
In Vitro and In Vivo HGF-Neutralization Activity of Humanized Anti-HGF YYB-101 mAb
To investigate the quality of the anti-HGF antibody produced in 5 L and 200 L bioreactors, the antibody was purified by affinity chromatography using a Protein A column. The affinity purified YYB-101 was further purified by sequential cation-exchange and anion-exchange chromatographies, with the flow-through fraction containing highly purified YYB-101 collected at each step. The flow-through fraction was subjected to a viral removal step, after which the YYB-101-producing CHO cells were cultivated in a 5 L bioreactor operated at the indicated pH or under a pH-shifting condition (shift from pH 7.2 to 7.0 on day 2). Viable cell density (A), viability (B), and YYB-101 titer in the culture medium (C) were measured during cultivation under the same conditions described in the legend for Fig. 2 .
antibody was concentrated by ultrafiltration. The purification and recovery yields in each step of the purification process are summarized in Table 4 . The purified YYB-101 mAb was homogeneous in terms of the molecular mass of both the heavy and light chains. Furthermore, there were no detectable levels of cleaved forms of YYB-101, even though as little as 0.3 µg of the purified antibody could be visualized by Coomassie Blue staining (Fig. 4A ) or western blot analysis with an anti-human IgG antibody (Fig. 4B) . Because soluble aggregates and charge variants are commonly found in recombinant mAb preparations, we performed SEC and cation-exchange HPLC to evaluate the product quality. The chromatograms of SEC (Fig. 4C ) and cation-exchange HPLC (Fig. 4D) showed that there were no apparent size or charge differences between the antibodies produced in the 5 L and 200 L bioreactors. More importantly, the purified YYB-101 mAb showed HGF-neutralizing activity in a cell-based assay in which the growth rescue effect of HGF in cultures of TGF-β-treated CCL-64 (Mv-1-Lu) mink lung epithelial cells was measured in the presence of increasing concentrations (0.01-10 µg/ml) of YYB-101. Serially diluted purified YYB-101 was preincubated with HGF for neutralization prior to adding the mixture to the TGF-β-treated CCL-64 cells. As shown in Fig. 5 , the anti-HGF YYB-101 mAbs produced in both the 5 L and 200 L bioreactors neutralized the HGF, and cell proliferation was inhibited almost to the level observed in the slower-growing control cultures because the inhibitory effect of TGF-β on cell proliferation could not be rescued by HGF in the presence of the neutralizing antibody.
We evaluated the in vivo biological activity of the anti-HGF YYB-101 mAb using a xenograft mouse model in which cells of the human glioblastoma-derived line U87 MG, which is known to contain an HGF/c-Met autocrine loop [31] , were implanted subcutaneously. When the tumor size reached 100 mm 3 , anti-HGF mAb was administered to each mouse (n = 10 per group) intraperitoneally twice per week at a dose of 0.5, 1.5, or 5.0 mg/kg. As shown in Fig. 6 , at a dose of either 1.5 or 5.0 mg/kg, the anti-HGF mAb dramatically inhibited tumor growth, whereas with a lower dose of anti-HGF mAb (0.5 mg/kg) or with human IgG used as a control (5.0 mg/kg), there was no noticeable inhibitory effect (Fig. 6 ). This result is the first clear demonstration of the in vivo antitumor activity of humanized anti-HGF YYB-101 mAb.
Discussion
The clinical applicability of mAbs has been limited because mouse-origin antibodies are immunogenic and therefore have low effector functions in humans. Recent developments in antibody engineering technologies enabled us to develop a humanized anti-HGF antibody, providing a satisfactory solution for this problem. We expressed the humanized anti-HGF mAb, designated YYB-101, using a serum-free suspension culture-adapted CHO cell line and Table 4 . Summary of humanized anti-HGF YYB-101 mAb purification.
Step showed its HGF-neutralizing activity using both a cellbased assay and a xenograft mouse model in which mice were subcutaneously implanted with human glioblastoma cells. The results demonstrated the ability of the YYB-101 mAb to block HGF/c-Met signaling. Despite considerable effort to develop therapeutic mAbs that block the HGF/c-MET interaction, to date only four antibodies have been developed for which their efficacy has been evaluated in preclinical and clinical trials. This includes three antihuman HGF mAbs, two of which (SCH900105/AV-299 and TAK-701) are humanized and are in clinical trial phases 2 and 1, respectively, and one fully human antibody (AMG102) currently in a phase 3 trial [10] . The remaining antibody is the anti-human c-MET mAb, designated MetMAb [14] . These mAbs, which inhibit activation of the HGF/c-MET pathway, showed promising clinical efficacy in c-MET-driven tumor patients. The humanized anti-HGF antibody YYB-101 is the first in this class of mAbs, in that it was generated by immunizing rabbits with the HGF/c-Met complex and its cDNA was further modified by phage display technology followed by gene manipulation. Currently, the YYB-101 mAb is undergoing preclinical studies. Media optimization is a critical step for large-scale production of antibodies. Owing to safety concerns related to transmissible spongiform encephalopathy and other contaminants, chemically defined media are usually chosen for large-scale mAb production. To increase cell density, culture viability, and productivity, animal-component-free hydrolysates are often added to chemically defined media [8, 11] . The hydrolysates, however, can be a significant source of medium variability owing to their complex composition and lot-to-lot variation and can thus cause problems in the downstream purification process. Hydrolysates were excluded from our optimized production medium, and instead we used a diverse array of fully chemically defined basal media and feed media. By optimizing the medium using diverse commercially available basal and feed media and establishing an optimal feeding strategy, we could increase antibody productivity by up to 7.5-fold compared with that achieved under non-optimized conditions.
Optimization of culture operating parameters, including physical factors such as temperature, gas flow rate, and agitation speed, and chemical factors such as DO, carbon dioxide, pH, and osmolality, is necessary for bioreactor operation. In this work, we focused on two parameters, DO and pH, which are known to be critical for antibody production. We found that shifting the pH from 7.2 to 7.0 during the early stage of culture was more effective at improving antibody productivity than maintaining a fixed pH of either 7.2 or 7.0. Higher pH levels (≥7.0) typically preferred for rapid cell growth usually lead to concomitant lactate accumulation [33] , which causes a decrease in pH and necessitates the addition of base to the reactor, resulting in an increase in osmolality and consequent detrimental effects on cell growth and viability. As shown in Fig. 3 , cell growth at pH 7.2 yielded a higher cell density, but cell viability decreased more rapidly compared with reactors operated at pH 7.0. However, induction of rapid cell growth by starting the culture at pH 7.2 and shifting the pH to 7.0 on day 2 resulted in an even higher cell density with a higher, longer-lasting viability, which appeared to be responsible for the dramatic increase in antibody productivity under the pH-shifting condition. We also found that the yield of YYB-101 mAb was higher with the 70% DO condition than with the lower 40% DO condition, although similar maximum cell numbers were obtained with both DO levels in the 5 L bioreactor.
We successfully scaled up the YYB-101 production process in a 200 L bioreactor based on the optimized medium, feeding strategy, and operating conditions, including pH shift and DO concentration. Maintenance of antibody quality during process scale-up is important in the production of therapeutic antibodies. Changes in the biochemical properties of antibodies can affect the therapeutic efficacy and pharmacokinetic behavior of the product. The HGFneutralization activity of the YYB-101 mAb produced in a 200 L bioreactor was similar to that of the antibody Data shown are the mean tumor volume ± SE for each treatment group. Asterisks indicate statistically significant differences between YYB-101-administered (1.5 mg/kg or 5 mg/kg) and control groups (*p < .01, **p < .001; Student's t-test).
recovered from a 5 L reactor operated under the 70% DO condition, suggesting that functional antibodies were produced in both bioreactors under the optimized running conditions. Previous studies showed that the DO level significantly affects antibody quality; although cell growth is relatively insensitive to DO in the range of 20-100% of air saturation, decreased glycosylation of antibody N-glycan chains was observed as the DO concentration was reduced [18, 21, 26] . In contrast to the 5 L bioreactor, the gas supply in the 200 L SUB was regulated with four mass-flow controllers, and DO was controlled during the early culture phase with pure O 2 . Under such DO-controlled conditions, both maximum cell density and volumetric productivity were increased compared with the 5 L bioreactor. Because the cell culture process can significantly alter product quality in terms of glycosylation, other posttranslational modifications, and impurity profiles, product quality, and potency must be confirmed during the course of process development and scale-up for the production of large amounts of therapeutic mAbs [4, 9, 35] . Using SEC and cation-exchange HPLC, we analyzed the YYB-101 mAb purified from both the 5 L and 200 L bioreactors and found that they displayed similar chromatograms as well as in vitro and in vivo biological activities, suggesting that a similar posttranslational modification of the antibody occurred in both reactors. However, there may have been microheterogeneities in the glycosylation patterns. Thus, glycan profiling using liquid chromatography-mass spectrometry should be carried out to test whether different degrees of glycosylation affect the therapeutic efficacy of YYB-101 by altering its HGF-binding activity and/or stability. In summary, we produced a humanized anti-HGF YYB-101 mAb under optimized medium and culture conditions and demonstrated for the first time that the antibody purified to near-homogeneity is capable of inhibiting tumor growth in a xenograft mouse model. Further studies are required to evaluate the toxicity and anticancer potency of the antibody in orthotropic tumor mouse models prior to its application in clinical trials. Nevertheless, our proof-ofconcept study shows that YYB-101 is a promising anticancer agent. Currently, YYB-101 is being evaluated in toxicity studies for upcoming clinical trials.
